IKT

Inhibikase Therapeutics Stock Analysis

AI Rating

Good
  • Quality6/10
  • Growth↑ 5/10
  • Value↑ 5/10
Inhibikase Therapeutics sales and earnings growth
IKT Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 27.12%
  • FCF Y/Y↓ -84.26%
Inhibikase Therapeutics gross and profit margin trends
IKT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -310.66%
Inhibikase Therapeutics net debt vs free cash flow
IKT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Inhibikase Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks